135038-17-4

Upstream product

• 93711-85-4 (2R)-2-[(2S,3S)-3-{(1R)-1-(t-butyldimethylsilyloxy)ethyl}-4-oxoazetidin-2-yl]propionic acid 
• 96035-98-2 (3S,4S)-4-<(1R)-1-benzyloxycarbonylethyl>-3-<(1R)-1-tert-butyldimethylsilyloxyethyl>-2-azetidinone 
• 135038-18-5 (R)-2-{(2S,3S)-1-(tert-Butyl-dimethyl-silanyl)-3-[1-(tert-butyl-dimethyl-silanyloxy)-vinyl]-4-oxo-azetidin-2-yl}-propionic acid benzyl ester 
• 135038-29-8 (R)-2-[(2S,3S)-3-(2-Bromo-acetyl)-1-(tert-butyl-dimethyl-silanyl)-4-oxo-azetidin-2-yl]-propionic acid benzyl ester 
• 135038-19-6 (R)-2-[(2S,3S)-3-(1-Hydroxy-2-iodo-ethyl)-4-oxo-azetidin-2-yl]-propionic acid benzyl ester 

Downstream Products

• 135096-42-3 (R)-benzyl 2-((2S,3S)-3-((1S)-1-hydroxyethyl)-4-oxoazetidin-2-yl)propanoate 

Relevant academic research and scientific papers

CARBAPENEM COMPOUNDS

This invention relates to carbapenem compounds, their stereoisomers, pharmaceutically acceptable salts or N-oxides thereof, which may be useful for the treatment of bacterial infections, particularly drug-resistant bacterial infections, as well as the pro

The synthesis of an asparenomycin analog

The synthesis of an analog of the carbapenem antibiotics, the asparenomycins, is described. This analog lacks the methyl group in the 6-alkylidene side chain while a methyl group has been placed at the 1β-position. The key step involved the Lewis acid-cat